Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma

• Ondrej Havranek ,

  * E-mail: ohavranek@mdanderson.org (OH); zdekleje@lf1.cuni.cz (ZK)

  Current Address: Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  Affiliation First Department of Medicine–Department of Hematology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic

  ⨯
• Petra Kleiblova,

  Affiliation Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

  ⨯
• Jan Hojny,

  Affiliation Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

  ⨯
• Filip Lhota,

  Affiliation Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

  ⨯
• Pavel Soucek,

  Affiliation Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic

  ⨯
• Marek Trneny,

  Affiliation First Department of Medicine–Department of Hematology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic

  ⨯
• Zdenek Kleibl

  * E-mail: ohavranek@mdanderson.org (OH); zdekleje@lf1.cuni.cz (ZK)

  Affiliation Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

  ⨯